SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement
more
Stories about Pharmaindustrie
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
moreGerresheimer at CPHI: focus on high-value solutions and sustainability
Duesseldorf (ots) - - Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy support - High-quality ready-to-fill solutions for biopharmaceuticals, cell and gene therapy - EcoDesign and environmentally friendly packaging options ensure greater sustainability Gerresheimer, an innovative system and solution ...
moreTakeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
moreNorgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
Amsterdam (ots/PRNewswire) - Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience and a unique blend of ...
moreHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
more- 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
morePatientGPT from Semalytix Will Replace Six Months of Evidence & Insight Generation in Life Science with Seconds
moreEmpowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced
Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...
moreArtilysin® - A Groundbreaking "Green Pharma" Solution
more- 2
Press Release: Aurubis subsidiary RETORTE expanding selenium production for profitable growth markets
One documentmore Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth / Phase II study for BC 007 in the indication Long COVID to start in June
moreCroma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China
Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...
moreLTS Lohmann Therapie-Systeme AG
LTS completes its entry into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
moreCroma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream ...
moreGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
moreAmicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
moreBjörn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...
moreNeuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Barcelona, Spain, Düsseldorf, Germany and Paris (ots/PRNewswire) - Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity Neuraxpharm Group ("Neuraxpharm"), the leading European specialty pharmaceutical company focused on ...
moreGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
moreLTS Lohmann Therapie-Systeme AG
LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the ...
moreGerresheimer with a good start to 2023 financial year: Again double-digit growth in revenues and Adjusted EBITDA
Düsseldorf (ots) - - First-quarter revenues grew organically by 21.0% - Adjusted EBITDA up organically by 24.8% - Gerresheimer confirms guidance for financial year 2023 Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug ...
One documentmoreSuccessful transaction: Adragos Pharma has officially taken over Clinigen’s development unit, Lamda Laboratories near Athens, Greece
Munich / London / Athens (ots) - - Adragos on a growth path: Three locations in Europe and five globally - Acquisition strengthens Adragos' end-to-end integrated pharmaceutical product development service offering - Agreement on further product development activities for Clinigen Munich-based pharmaceutical contract ...
morePress release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
One documentmoreGenialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
moreDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
moreDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
moreAdragos Pharma acquires Clinigen’s development unit, Lamda Laboratories
Munich / London / Athens (ots) - - Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment - Agreement includes further product development activities for Clinigen Limited - Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich-based pharmaceutical contract ...
more
Previous123456Next